Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Tirzepatide is an approved, prescribable medicine; retatrutide is still investigational with no approved product anywhere. That access difference — not trial percentages — is the practical distinction for anyone comparing the two today.
Retatrutide's Phase 3 results have made it one of the most searched weight-management topics, but unlike tirzepatide it cannot yet be legally prescribed or compounded. This comparison explains the regulatory difference, why cross-trial weight-loss numbers should not be compared directly, and what to ask a clinic that mentions either.
New to the medicine itself? Our reference page on retatrutide explains what it is, what the trials show and what a credible clinic should tell you about it before approval.
Related comparison paths
Move from this comparison into the peptide pages and relevant clinic profiles.
Both are Eli Lilly medicines, and the difference that matters today is access: tirzepatide is FDA approved and prescribed in the US now, while retatrutide is an investigational drug that no regulator has approved.[1][6] Every fact below names its source, and each source was read on November 4, 2026.
Retatrutide
Tirzepatide
How it works
Retatrutide:Triple agonist: one molecule that acts on the GIP, GLP-1 and glucagon receptors[1]
Tirzepatide:Dual agonist: acts on the GLP-1 and GIP receptors[6]
FDA status
Retatrutide:Not approved for any use, by the FDA or any regulator in the world. Investigational[1]
Tirzepatide:FDA approved as Zepbound for chronic weight management (November 8, 2023) and as Mounjaro for type 2 diabetes[6]
Can you be prescribed it in the US?
Retatrutide:No. Lilly says it is legally available only to participants in its clinical trials, and the FDA says it cannot be used in compounding under federal law[3][7]
Tirzepatide:Yes. Brand-name Zepbound or Mounjaro, or a compounded version from a licensed pharmacy (compounded drugs are not FDA approved)[6][7]
Largest Phase 3 weight result, highest dose tested
Retatrutide:TRIUMPH-1: average 25.0% at 80 weeks (placebo 3.9%), treatment-regimen estimand; 28.3% (placebo 2.2%) by the efficacy estimand[3]
Tirzepatide:SURMOUNT-1: average 20.9% at 72 weeks (placebo 3.1%), treatment-regimen estimand[4]
Head-to-head trial
Retatrutide:TRIUMPH-5 (NCT06662383) compares the two directly over about 80 weeks. It is ongoing and has not reported[5]
Tirzepatide:The same trial
What comes next
Retatrutide:Lilly plans to submit its application to the FDA in Q1 2027. No filing has been announced[2][10]
Tirzepatide:Already prescribed in the US
Why the trial numbers are not a head-to-head result
The two weight figures in the table come from different trials. SURMOUNT-1 followed 2,539 adults on tirzepatide or placebo for 72 weeks.[4] TRIUMPH-1 followed 2,339 adults on retatrutide or placebo for 80 weeks. Both enrolled adults with obesity, or overweight with a weight-related condition, and without diabetes, but they were run separately, years apart and for different lengths of time.[3] Comparing one trial's average with another's is unreliable, and neither average is a promise of what any one person would lose. The table uses the treatment-regimen figure for both, which counts people who stopped treatment, so that the two are at least measured the same way.
The direct comparison is Lilly's TRIUMPH-5 trial (NCT06662383): about 800 adults with obesity, with or without type 2 diabetes, randomized to retatrutide or tirzepatide, with the change in body weight at 80 weeks as the main result. It is ongoing and has not reported.[5] The head-to-head result Lilly announced on October 28, 2026, TRANSCEND-T2D-2, compared retatrutide with Ozempic (semaglutide) in people with type 2 diabetes, not with tirzepatide: average weight change at 80 weeks was 20.9% on the higher retatrutide dose against 9.4% on Ozempic, by the efficacy estimand.[1]
In TRIUMPH-1 the most common side effects of retatrutide were digestive: nausea, diarrhea, constipation and vomiting, more often at higher doses, and 11.3% of people on the highest dose stopped treatment because of side effects, against 4.9% on placebo.[3] Retatrutide's longer-term safety data are still being collected.
When could retatrutide be available?
There is no release date. As of November 4, 2026, Lilly says retatrutide has not been approved by the FDA or any regulator anywhere in the world.[1] Lilly's stated plan is to submit a Biologics License Application to the FDA in the first quarter of 2027, and that was still the reported timeline on October 28, 2026.[2][10] Lilly and the FDA are also in litigation over whether retatrutide should be reviewed as a biologic or as a drug, and Lilly's chief executive said in August 2026 that a rejected biologic application could delay it.[9] An FDA review follows a filing and takes months, and its outcome is not guaranteed. We will update this section when Lilly confirms a filing or the FDA publishes a decision.
Do not buy “retatrutide” online
Websites selling “retatrutide” are selling vials labeled for research use or “not for human consumption”. Research peptides are not for human use. The FDA has warned companies selling retatrutide under those labels, says such products are of unknown quality and may be harmful, and urges consumers not to buy them; it also says retatrutide cannot be used in compounding under federal law, so there is no legitimate “compounded retatrutide”.[7]
Lilly says no medicine containing retatrutide has been approved for human use anywhere and that it cannot be sold to consumers. In August 2026 it filed six lawsuits against US sellers, and its chief medical officer said what is sold on the black market “is not a medicine”.[8] Peptide Clinic Finder does not list, link or review any seller of retatrutide. A clinic or website offering it today is a red flag.
Available now in the US: tirzepatide
Of the two, tirzepatide is the one you can be prescribed. Brand-name Zepbound and Mounjaro are FDA approved.[6] US telehealth programs also prescribe compounded tirzepatide, prepared by a licensed compounding pharmacy for an individual prescription after a clinician review; compounded drugs are not FDA approved.[7] Whether any of them suits you is a clinician's decision, and a prescription is never guaranteed.
In our latest read, compounded tirzepatide costs $69 to $399 a month on a month to month plan across 13 US online programs (checked November 19, 2026), with a median of $139.
Compounded medications are not FDA approved and are not evaluated by the FDA for safety or effectiveness. Welludr LLC provides technology and non-clinical administrative support; a licensed clinician makes all diagnosis and prescribing decisions using independent clinical judgment; a prescription is never guaranteed. PCF may earn a commission if you sign up. This placement does not affect our rankings or editorial assessment.
Regulatory note: After the FDA declared the semaglutide shortage resolved in February 2025, pharmacies could no longer routinely compound copies of that licensed product. On May 1, 2026 the FDA published a notice proposing not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List; a final determination is still pending. The availability and pricing described here may not reflect what a provider can currently supply, so confirm the current offering and cost directly with any provider before relying on it.Last reviewed: July 2026
Nobody can say yet. Retatrutide's Phase 3 trials reported larger average weight loss than tirzepatide's trials did, but those were separate trials, run years apart and for different lengths of time, so the numbers cannot be compared directly. The trial that compares the two head to head, Lilly's TRIUMPH-5, is still running and has not reported, so there is no direct answer yet.
Is retatrutide FDA approved?
No. As of November 4, 2026, Lilly says retatrutide has not been approved by the FDA or any regulator anywhere in the world. Lilly's stated plan is to submit its application to the FDA in the first quarter of 2027, and no filing has been announced. An FDA review follows a filing and takes months, and approval is not guaranteed.
Can I switch from tirzepatide to retatrutide?
Not outside a clinical trial. Retatrutide cannot be prescribed in the US, and the FDA says it cannot be used in compounding under federal law, so no clinic or pharmacy can legally supply it to you. Lilly says it is legally available only to participants in its clinical trials. Any decision about your current treatment is one to make with your prescriber.
Is it safe to buy retatrutide online?
No. Websites selling "retatrutide" labeled for research use are selling an unapproved, unregulated product. The FDA has warned sellers of these products and urges consumers not to buy them, saying they are of unknown quality and may be harmful. Lilly has sued sellers and calls what is sold on the black market "not a medicine". Peptide Clinic Finder does not list or link any seller.
What can I get now instead?
Tirzepatide. Brand-name Zepbound and Mounjaro are FDA approved, and US telehealth programs prescribe compounded tirzepatide after a clinician review. In our latest read, compounded tirzepatide costs $69 to $399 a month on a month to month plan (checked November 19, 2026). Compounded medicines are not FDA approved, and whether any of them suits you is a clinician's decision.
Sources
Each numbered reference above points to one of these. Trial figures are quoted as the source reports them.
Eli Lilly press release, October 28, 2026: TRANSCEND-T2D-2 (NCT06260722) topline results, retatrutide vs Ozempic in type 2 diabetes. States retatrutide has not been approved by the FDA or any regulator anywhere in the world. investor.lilly.com. Read November 4, 2026.
Eli Lilly press release, September 29, 2026: TRIUMPH-2 full results. States Lilly plans to submit a Biologics License Application to the FDA in Q1 2027, and that retatrutide cannot be legally sold or marketed for human use. investor.lilly.com. Read November 4, 2026.
Eli Lilly press release, May 21, 2026: TRIUMPH-1 (NCT05929066) topline results, 2,339 adults with obesity or overweight without diabetes, 80 weeks. investor.lilly.com. Read November 4, 2026.
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 2022;387:205-216, PubMed 35658024. pubmed.ncbi.nlm.nih.gov. Read November 4, 2026.
Lilly Medical: How does retatrutide compare with other incretin-based therapies? (TRIUMPH-5, NCT06662383, retatrutide vs tirzepatide, ongoing), last reviewed April 21, 2026. medical.lilly.com. Read November 4, 2026.
FDA press release, November 8, 2023: FDA approves new medication for chronic weight management (Zepbound, tirzepatide; already approved as Mounjaro for type 2 diabetes), as distributed by PR Newswire. www.biospace.com. Read November 4, 2026.
FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (compounded drugs are not FDA approved; retatrutide sold "for research purposes"; retatrutide cannot be used in compounding under federal law), content current as of October 1, 2026. www.fda.gov. Read November 4, 2026.
Eli Lilly press release, August 12, 2026: Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (six lawsuits filed). lilly.gcs-web.com. Read November 4, 2026.
BioSpace, August 5, 2026: Lilly, FDA retatrutide biologic dispute comes to a head as submission nears (BLA vs NDA litigation; Lilly CEO on timing). www.biospace.com. Read November 4, 2026.
BioSpace, October 28, 2026: Lilly's retatrutide trounces Novo's Ozempic in diabetes, weight loss (application expected in Q1 2027). www.biospace.com. Read November 4, 2026.
This section is information, not medical advice. It does not recommend retatrutide or any other medicine, and it gives no dosing guidance. Talk to a licensed clinician about what is appropriate for you.
Next step
Compare clinics offering these treatments
Use city pages and peptide-specific pages to move from general research into actual provider shortlists. That usually gives a better buying picture than comparing drug names alone.
Lilly's triple agonist is in Phase 3 trials and is not yet approved or available anywhere. Our US retatrutide guide sets out the trial results as reported, with their sources, where it stands with the FDA, why it has no price, and what you can be prescribed today.